Abbott to buy Chile’s CFR for $3bn


US medical products specialist Abbott has agreed to buy Chilean generic drugmaker CFR Pharmaceuticals for $2.9 billion (£1.7 billion), and will take on $430 million of CFR’s debt.

The move will bolster Abbott’s position in the rapidly growing markets of Latin America, expanding the company by around 7000 employees at R&D and manufacturing facilities in Chile, Colombia, Peru and Argentina. Abbott will also get access to CFR’s portfolio of over 1000 branded generic drugs and other products, as well as its distribution networks across the region.


Related Content

Abbot boosts heart devices with St Jude buyout

6 May 2016 Business

news image

Medical devices consolidation continues with $25bn deal, but Abbott expresses concerns over proposed Alere merger

Medical devices consolidation continues

4 February 2016 Business

news image

Abbott to buy Alere for $5.8bn to augment its point-of-care diagnostics business

Most Commented

Electric choc treatment promises lower fat chocolate

22 June 2016 Research

news image

Problem of reduced fat chocolate gumming up factories’ pipelines overcome

UK plans stricter controls on poisons and explosives

7 August 2014 News and Analysis

news image

The government will use licenses to track the sale of hazardous substances